UBS Group’s Oaktree Acquisition Corp III Life Sciences Unit OACCU Stock Holding History

UBS Group’s Portfolio OACCU Stock Details OACCU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104K	Sell	9,464 -301	-3%	-$3.29K	﹤0.01%	7169
2026 Q1	$104K	Hold	9,765	–	–	﹤0.01%	6985
2025 Q4	$104K	Sell	9,765 -18	-0.2%	-$194	﹤0.01%	6897
2025 Q3	$104K	Hold	9,783	–	–	﹤0.01%	7103
2025 Q2	$104K	Buy	9,783 +300	+3%	+$3.16K	﹤0.01%	7210
2025 Q1	$99K	Hold	9,483	–	–	﹤0.01%	7058
2024 Q4	$95.9K	Buy	+9,483	New	+$95.5K	﹤0.01%	6903

Other funds holding OACCU

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Athos Capital Hong Kong $282M AUM 11.4% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group's OACCU Position: Q2 2026 in Review

UBS Group reduced its Oaktree Acquisition Corp III Life Sciences Unit (OACCU) stake by 3.1% in Q2 2026, selling an estimated $3.29K and leaving 9,464 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #7169.

UBS Group first reported a position in OACCU in Q4 2024 and has held it in 7 quarters since. 5 funds tracked by Wall St. Rank hold OACCU as of Q2 2026.

UBS Group held 9,464 shares of Oaktree Acquisition Corp III Life Sciences Unit worth $104K as of Q2 2026.
UBS Group sold 301 Oaktree Acquisition Corp III Life Sciences Unit shares in Q2 2026, an estimated $3.29K.
Oaktree Acquisition Corp III Life Sciences Unit made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7169 holding.
UBS Group first reported a position in Oaktree Acquisition Corp III Life Sciences Unit in Q4 2024 and has held it in 7 quarters since.
5 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Unit as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.